Stockscreener 앱 받기
13.00
2.48%
-0.33
Corbus Pharmaceuticals Holdings Inc 주식(CRBP)의 최신 뉴스
Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Analysts Set Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) PT at $62.00 - MarketBeat
(CRBP) Investment Report - Stock Traders Daily
Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Mizuho remains bullish on Corbus stock, sees encouraging outlook for Nectin-4 ADC - Investing.com Canada
Charles Schwab Investment Management Inc. Buys 64,800 Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) - MarketBeat
Charles Schwab Investment Management Inc. Boosts Stock Position in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) - Defense World
Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch
Corbus Pharmaceuticals' SWOT analysis: stock's potential in cancer and obesity - Investing.com
Corbus Pharmaceuticals Holdings Inc. stock remains steady Friday, underperforms market - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Corbus begins phase 1 trial for advanced solid tumors By Investing.com - Investing.com South Africa
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day - MarketWatch
Corbus begins phase 1 trial for advanced solid tumors - Investing.com
Corbus Pharmaceuticals Announces Dosing of First Patient in its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors - The Manila Times
Corbus Pharmaceuticals Announces Dosing of First Patient in - GlobeNewswire
Corbus Pharma Launches Phase 1 Trial for Novel Cancer Immunotherapy CRB-601 - StockTitan
2 'Strong Buy' Biotech Stocks With 120% or More Upside Potential - MSN
Eli Lilly and Company (LLY-N) QuotePress Release - The Globe and Mail
Trading (CRBP) With Integrated Risk Controls - Stock Traders Daily
Walleye Capital LLC Sells 113,428 Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) - MarketBeat
Why Is Corbus Pharmaceuticals Holdings, Inc. (CRBP) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds? - Insider Monkey
FDA fast tracks Corbus drug for cervical cancer treatment By Investing.com - Investing.com Canada
Corbus Pharmaceuticals' CRB-701 Receives FDA Fast Track Designation for Metastatic Cervical Cancer Treatment - Marketscreener.com
Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits - Quantisnow
Piper Sandler Initiates Coverage of Corbus Pharmaceuticals Holdings (CRBP) with Overweight Recommendation - MSN
HighVista Strategies LLC Acquires 36,499 Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) - MarketBeat
FDA fast tracks Corbus drug for cervical cancer treatment - Investing.com
FDA Grants Fast Track Designation to CRB-701 for the Treatment of Relapsed or Refractory Metastatic Cervical Cancer - GlobeNewswire
Corbus Pharma Secures FDA Fast Track Status for Cancer Drug CRB-701 - StockTitan
CRBP (Corbus Pharmaceuticals Holdings) Financial Strength : 8 (As of Sep. 2024) - GuruFocus.com
Corbus Pharmaceuticals stock rated Overweight, CRB-701 could drive solid tumor efficacy - Investing.com Canada
Corbus Pharmaceuticals Holdings Inc. stock rises Monday, still underperforms market - MarketWatch
Corbus, Viking initiated at overweight by Piper Sandler (NASDAQ:VKTX) - Seeking Alpha
CRBP (Corbus Pharmaceuticals Holdings) Enterprise Value : $61.43 Mil (As of Dec. 02, 2024) - GuruFocus.com
Victory Capital Management Inc. Boosts Holdings in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) - Defense World
Acuta Capital Partners LLC Reduces Stock Holdings in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) - MarketBeat
Corbus Pharmaceuticals Holdings Inc. stock rises Tuesday, still underperforms market - MarketWatch
Corbus Pharmaceuticals Holdings, Inc. (CRBP): An Oversold Healthcare Stock to Invest In Now - Insider Monkey
CRBP (Corbus Pharmaceuticals Holdings) Change In Working Ca - GuruFocus.com
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Receives Average Rating of "Buy" from Analysts - MarketBeat
Corbus Pharmaceuticals to Present at the 7th Annual Evercore HealthCONx Conference - Investing.com Australia
CRBPCorbus Pharmaceuticals Holdings, Inc. Latest Stock News & Market Updates - StockTitan
Corbus Pharmaceuticals to Present at Evercore HealthCONx Conference in December | CRBP Stock News - StockTitan
2.88%
2.65%
자본화:
|
볼륨(24시간):